Cas:15797-52-1 4-[3,5-bis(4-hydroxyphenyl)phenyl]phenol manufacturer & supplier

Chemical Name:4-[3,5-bis(4-hydroxyphenyl)phenyl]phenol

CAS.NO:15797-52-1

Synonyms:MFCD01321328;1,3,5-tris(4-hydroxyphenyl)benzene

Molecular Formula:C₂₄H₁₈O₃

Molecular Weight:354.39800

HS Code:

Physical and Chemical Properties:

Melting point:233-240ºC(lit.)

Boiling point:572.3ºC at 760 mmHg

Density:1.263g/cm3

Index of Refraction:1.677

PSA:60.69000

Exact Mass:354.12600

LogP:5.80440

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:NONH for all modes of transpor

Packing Group:

Contact us for information like MFCD01321328 chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,1,3,5-tris(4-hydroxyphenyl)benzene physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,1,3,5-tris(4-hydroxyphenyl)benzene Use and application,1,3,5-tris(4-hydroxyphenyl)benzene technical grade,usp/ep/jp grade.

Related News: AstraZeneca Plc said on Monday that its cancer drug met the main goal of delaying the progression of a form of lung cancer. 4-[3,5-bis(4-hydroxyphenyl)phenyl]phenol manufacturer Jo Soden, Co-managing Director of Retrogenix, said ��We look forward to working with Resonant to deconvolute the targets for their antibodies. Resonant��s innovative platform is delivering functional therapeutic candidates at rapid pace and we welcome the opportunity to identify the specific, biologically-relevant targets which will help progress these leads towards promising new therapies for patients with cancer.�� 4-[3,5-bis(4-hydroxyphenyl)phenyl]phenol supplier The U.K. government previously purchased more than 380 million rapid tests from Innova, to help set up programs capable of screening millions of people per day—in the run-up to offering free COVID-19 testing nationwide at least twice per week. 4-[3,5-bis(4-hydroxyphenyl)phenyl]phenol vendor Jo Soden, Co-managing Director of Retrogenix, said ��We look forward to working with Resonant to deconvolute the targets for their antibodies. Resonant��s innovative platform is delivering functional therapeutic candidates at rapid pace and we welcome the opportunity to identify the specific, biologically-relevant targets which will help progress these leads towards promising new therapies for patients with cancer.�� 4-[3,5-bis(4-hydroxyphenyl)phenyl]phenol factory Jo Soden, Co-managing Director of Retrogenix, said ��We look forward to working with Resonant to deconvolute the targets for their antibodies. Resonant��s innovative platform is delivering functional therapeutic candidates at rapid pace and we welcome the opportunity to identify the specific, biologically-relevant targets which will help progress these leads towards promising new therapies for patients with cancer.��